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Acinetobacter baumannii is a Gram-negative bacterial pathogen responsible for a 
range of nosocomial infections. The recent rise and spread of multidrug resistant A. 
baumannii clones has fueled a search for alternative therapies, including bacteriophage 
endolysins with potent antibacterial activities. A common feature of these lysins is the 
presence of a highly positively charged C-terminal domain with a likely role in 
promoting outer membrane penetration. In the current study, we show that the C-terminal 
amino acids 108-138 of phage lysin PlyF307, named P307, alone was sufficient to kill A. 
baumannii (>3-logs). Furthermore, P307 could be engineered for improved activity, the 
most active derivative being P307SQ-8C (>5-log kill). Both P307 and P307SQ-8C showed 
high in vitro activity against A. baumannii in biofilms. Moreover, P307SQ-8C exhibited 
MICs comparable to levofloxacin and ceftazidime and acted synergistically with 
polymyxin B. While the peptides were shown to kill by disrupting the bacterial 
cytoplasmic membrane, they did not lyse human red blood cells or B cells; however, 
serum was found to be inhibitory to lytic activity. In a murine model of A. baumannii 
skin infection, P307SQ-8C reduced the bacterial burden by ~2-logs in 2 h. This study 
demonstrates the prospect of using peptide derivatives from bacteriophage lysins to treat 
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1 CHAPTER 1 – INTRODUCTION 
1.1  Acinetobacter baumannii 
 Acinetobacter baumannii is a strictly aerobic Gram-negative bacterium and 
belongs to the family Moraxellaceae. As an opportunistic pathogen, it causes hospital-
acquired or nosocomial infections worldwide (1). The treatment options are greatly 
limited by its intrinsic and acquired resistance to all classes of antibiotics (2, 3). 
1.1.1  History 
 The designation of A. baumannii has changed a great deal over time. When first 
reported by Beijerinck in 1911, A. baumannii was characterized as a soil bacterium and 
was called Micrococcus calcoaceticus (4, 5). Only in the 1950s did it acquire its current 
genus identification Acinetobacter after being known under various genera, such as 
Achromobacter anitratus, Moraxella lwoffii, Neisseria winogradskyi, to name just a few. 
Current nomenclature, suggested by Brisou and Prevot in 1954, stemmed from the 
bacterium’s non-motile phenotype (akinetos meaning non-motile in Greek) and was 
officially recorded with a single species A. calcoaceticus in Bergey’s Manual of 
Systematic Bacteriology in 1974 (6, 7). Presently the Acinetobacter genus contains over 
50 species among which A. baumannii, A. calcoaceticus, A. haemolyticus, A. 
nosocomialis and A. pittii are of high clinical relevance and A. baumannii is the most 
prominent with highest morbidity and mortality rate (6-8). 
Not only has the nomenclature evolved but the antibiotic susceptibility has also 
changed over the last century for A. baumannii. During the 1960s and early 70s, 
nosocomial infections by Acinetobacter had already been reported in Europe and the 
United States despite limited methods for pathogen identification. The etiologic agents of 
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these outbreaks, still called Acinetobacter anitratus, were of low pathogenicity and could 
be easily controlled by β-lactams, sulfonamides and aminoglycosides (9). However, 
beginning in late 70s, 80s and 90s, these antibiotics had progressively become ineffective 
and multidrug-resistant clones emerged worldwide (10, 11). In addition, advances in 
molecular techniques during these decades enabled the identification of baumannii 
species as the cause of the majority of Acinetobacter infections (6). In the 2000s and 
2010s, problems with antibiotic-resistant A. baumannii worsened resulting in the 
establishment of surveillance networks worldwide to increase awareness and better 
containment (6). Notably in 2006, The Infectious Diseases Society of America included 
A. baumannii in the list of ESKAPE pathogens (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa and 
Enterobacter spp.) for which only limited treatment options were available (12). 
Moreover, in February 2017, the World Health Organization (WHO) emphasized the 
urgent need for new drugs against this pathogen by listing Acinetobacter in the most 
critical category on which research and development (R&D) efforts for new antibiotics 
should be focused (13). A. baumannii has risen from a harmless bacterium to one of the 
most clinically severe pathogens in the past century (Figure 1.1). To stay ahead of this 
pathogen, diverse strategies must be concurrently employed, including but not limited to 




MDR – multidrug resistant; XDR – extensively drug resistant; PDR – pandrug resistant; 
TATFAR – Transatlantic Taskforce on Antimicrobial Resistance; CDC - Center of 
Disease Control and Prevention; SENTRY, ReLAVRE and RHOVE – antimicrobial 
surveillance program 
Figure 1.1 Significant events in the history of A. baumannii. 
The timeline consists of three milestones, (i) awareness and diagnosis, (ii) rise of 
antibiotic resistance, and (iii) resistance containment and surveillance efforts by 
international organizations. Adapted by permission (Creative Commons Attribution 
License) from Hindawi Publishing Corporation: Journal of Pathogens (6), copyright 
2016.
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 1.1.2 Prevalence and pathogenesis 
 A. baumannii is an increasingly significant opportunistic pathogen worldwide (2). 
Its natural habitats are soil and water. In healthy children and immuno-compromised 
adults, it can cause community-acquired respiratory tract infections (7). Community-
acquired pneumonia is currently limited to the tropical regions of the world and occurs 
during warm and humid months (14). However, nosocomial infections are prevailing in 
healthcare facilities worldwide. The important reservoirs in hospital outbreaks are 
patients, healthcare workers and equipment (15). A. baumannii also persists for long 
periods on abiotic surfaces under dry conditions (16). From contaminated indwelling 
devices, surgical equipment and ventilators, A. baumannii can infect various body sites 
(Figure 1.2) and cause meningitis, keratitis, opthalmitis, wound, respiratory and urinary 
tract infections, pneumonia and bacteremia (17). According to the CDC report in 2013, 
7,300 clinical isolates out of 12,000 Acinetobacter cases were multi-drug resistant 
(untreatable by three or more antibiotic categories) and 500 deaths were attributed to 
those infections annually in the United States alone (18). Given the widespread 
prevalence and severe pathogenesis, it is essential to develop new strategies to control A. 




Figure 1.2 Pathogenesis and virulence of A. baumannii. 
A. baumannii colonizes different parts of the body and causes infections when 
opportunities arise (e.g. weakened immune system, skin lesions, etc.) The pathogen has 
high tolerance to environmental stress, creating inanimate reservoirs in healthcare 
settings. With its varied virulence factors and antibiotic resistance, A. baumannii is 
indeed a formidable foe in hospitals. Reprinted by permission from Macmillan Publishers 
Limited: Nature Reviews Microbiology (17), copyright 2007. 
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1.1.3 Virulence and antibiotic resistance 
 A. baumannii employs several virulence factors to compromise host cells and 
evade immune system (Figure 1.2). The factors include outer membrane proteins (Omp), 
secretion systems, toxins, iron-chelating siderophores, capsule and lipopolysaccharide 
(LPS). Like other Gram-negative bacteria, A. baumannii utilizes Omp for adherence, 
invasion and cytotoxicity, e.g. OmpA has been shown to be essential for epithelial cell 
binding and for producing outer membrane vesicles that deliver virulence factors to 
human host cells (19-22). The Type II secretion system is used to secrete lipases, 
proteases and toxins that are important for in vivo fitness and pathogenesis (23). After 
invasion, A. baumannii survives in iron-limiting host environments by utilizing 
siderophores (24). Last, but not least, A. baumannii achieves serum resistance, eludes 
complement, neutrophils and antibodies by capsule (25) and modified LPS (26). 
Besides the virulence factors, A. baumannii possesses assorted mechanisms of 
antibiotic resistance (27). Being naturally competent, the pathogen is capable of taking up 
environmental DNA for increased survival advantages (28). Other modes of horizontal 
gene transfer such as plasmid conjugation and bacteriophage transduction have resulted 
in the expansion of its chromosomal repertoire for drug resistance (7). The intrinsic and 
acquired resistance mechanisms (Table 1.1) include low permeability that limits 
antibiotic uptake, efflux pumps that decrease intracellular antibiotic concentration, 
biofilm formation that restricts metabolism to attenuate antibiotic effect, antibiotic target 
site mutations and antibiotic-deactivating enzymes (27). As a result, most of A. 
baumannii clinical isolates these days are either multi-drug resistant (MDR) or 
extensively drug resistant (XDR or susceptible to only one or two classes of antibiotics) 
or pan-drug resistant (PDR or resistant to all antibiotics).
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1.1.4 Treatment 
 A. baumannii has successfully overcome most of the clinically approved 
antibiotics with one or more of the resistance mechanisms mentioned above. As such, the 
treatment options are limited. The antibiotics for A. baumannii infections have 
traditionally been cephalosporins, sulbactam, carbepenems, rifampin, fluoroquinolones, 
aminoglycosides, tetracyclines and polymyxins (Table 1.1). The first three classes, being 
of β-lactam family, target the peptidoglycan synthesis and A. baumannii neutralizes them 
by class A-D β-lactamases and penicillin-binding proteins (PBPs). To counteract 
rifampin, fluoroquinolones and aminoglycosides, A. baumannii strains with mutations in 
the drug binding sites of RNA polymerase, DNA topoisomerase and ribosome 
respectively have arisen. Tetracyclines, protein synthesis inhibitors, are blocked by Tet 
proteins that bind to 70S ribosome for protection. Polymyxins kill A. baumannii by 
interacting with LPS through positively charged Dab (α,γ-diaminobutyric acid) residues 
and destabilizing the outer membrane.  Even the drugs of last resort, polymyxins are 
marred with suboptimal pharmacokinetics and safety issues as well as resistance by LPS 
modification. Currently, PDR A. baumannii infections are treated with combination 
therapy, i.e. two or more drugs that are shown to have in vitro synergy (e.g. colistin and 
rifampin). However, clinical trial data relevant to the efficacy of mono therapy vs. 
combination therapy are limited since most of the latter have so far been salvage options 
for severe cases (29). In view of the lack of novel antibiotic class to treat A. baumannii 
and the increasing threat of drug resistance, alternative strategies such as phage-based 
therapy must be considered and analyzed to fill the unmet need. 
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Table 1.1 Antibiotics versus A. baumannii (29) 
Classes of 
antibiotics 
Targets Resistance mechanisms 
Cephalosporins Cell wall synthesis Acinetobacter-derived cephalosprinase 
(ADC), extended spectrum β-lactamases 
(ESBL)  
Carbepenems Cell wall synthesis Carbepenamases (OXA-groups, metallo-
β-lactamases), reduced permeability, 
active efflux 
Sulbactam β-lactamases or PBPs Reduced expression of the targets 
Rifampin RNA polymerase RNA polymerase modification, rifampin 
modifying enzyme, active efflux 
Aminoglycosides 16S ribosomal RNA 
(protein synthesis) 
16S ribosomal RNA modification, 
aminoglycoside modifying enzymes 
Fluoroquinolones DNA gyrase and 
topoisomerase 
Modifications in the quinolone resistance 
determining region, active efflux 
Colistin LPS LPS modification or loss 
Tetracyclines 30S ribosomal RNA 
(protein synthesis) 
Ribosomal protection proteins, active 
efflux  
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1.2 Alternative antibacterial agents 
1.2.1 Bacteriophages 
The interest in bacteriophage therapy has been rekindled by the rise of drug-
resistant bacteria together with the lack of new antibiotics in the R&D pipeline (30). The 
discovery and characterization of phages in 1917 and the subsequent demonstration of 
their therapeutic potential predated the beginning of antibiotic era by 11 years. However, 
after the industrialization of penicillin and subsequent drugs, only the former Soviet 
Union and Eastern Europe continued to pursue phage studies and use phage cocktails to 
treat bacterial infections. The rest of the world had switched away from phage 
therapeutics to antibiotics for a number of reasons: efficacy, safety, resistance, 
manufacturing (31). Now, with the imminent possibility that we may be entering a post-
antibiotic era, western research institutions and government agencies are re-considering 
this century-old biological approach to kill bacteria (32, 33). 
Before phages can be introduced to clinics in the western world, barriers must be 
overcome to obtain regulatory approval (34). A few of the hurdles originate from the 
nature of phage reproduction. Phages, as viruses of bacteria, can adopt lysogenic or lytic 
life cycles to multiply. After injecting their DNA into bacteria, temperate phages can 
display lysogenic cycle and replicate along as prophages until environmental cues induce 
them to enter a lytic cycle. On the other hand, virulent phages display lytic cycle only and 
assemble phage progeny using cellular machineries of bacteria. The lytic cycle 
culminates in bacterial lysis and release of phages to infect neighboring bacteria (Figure 
1.3). Therefore, lytic phages, regardless of being virulent or temperate, could 
theoretically multiply at the site of application and lower the bacterial burden to control 
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infections. However, the use of temperate phages can spread antibiotic resistance genes 
since phages can act as carriers of genetic materials among bacteria. Another safety 
concern is the activation of detrimental inflammatory responses to the released bacterial 
components (and endotoxins in the case of Gram-negative bacteria) by massive bacterial 
lysis. In addition, phages are often strain-specific and phage cocktails are required to 
cover a single species of pathogen. On the flip side, the specificity can sometimes limit 
the unintended killing of commensal microflora. Like antibiotics, phage cocktails can 
become ineffective as bacteria develop resistance. Therefore the treatments must be 
monitored and modified. Phage resistance, however, is more easily tackled than antibiotic 
resistance due to the tremendous diversity of phages for some species in nature resulting 
from the arms race between phages and bacteria through hundreds of millions of years. 
Unfortunately, the diversity could mean more regulatory requirements (31, 34). For these 
reasons and others, phages have yet to appear in western clinics. 
Despite the barriers and challenges, a number of strategies are in place to bring 
the phages from bench to bedside. One such approach is genetically engineering phages 
for different purposes. Some engineering tactics include creating: phages with reduced 
lysis to mitigate inflammatory responses; phages that increase antibiotic susceptibility of 
bacteria; phages that target pathogens with DNA sequence specificity, e.g. antibiotic 
resistance genes; phages with broader host ranges and so forth (35). Along with these 
creative scientific efforts, more clinical data are required to acquire regulatory approval. 
Although the long-established use of phage therapy in Russia, Poland and Georgia should 
have warranted the efficacy and safety, those clinical trials were not conducted with 
appropriate controls, and so the Eastern European experience has not provided any useful 
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proof of efficacy by Western standards. To fill this knowledge gap, the Phagoburn 
clinical trial, funded by European Commission, is in progress to access the efficacy and 
safety of phages in treating burn wounds infected by Escherichia coli or Pseudomonas 
aeruginosa (ClinicalTrials.gov Identifier NCT02116010). The results from all the 
scientific and clinical endeavors may pave the way for phages towards clinical use. 
 
 Figure 1.3 Life cycles of virulent and temperate phages. 
After phage attachment and DNA injection into host bacteria, virulent phages display 
lytic cycle whereas temperate phages can enter either lytic or lysogenic cycle. During the 
lytic cycle, phages multiply inside bacteria and the fate of the host is lysis. On the other 
hand, phages replicate along with host bacteria as prophages during the lysogenic cycle. 
The host bacteria or lysogens survive until prophages re-enter lytic cycle by environment 
cues (e.g. UV damage to DNA). As phages multiply, they can package bacterial DNA 
and bring about transduction or phage-mediated horizontal gene transfer among bacteria. 
Adapted by permission from American Society for Microbiology: Antimicrobial Agents 
and Chemotherapy (31), copyright 2001. 
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1.2.2 Phage lysins 
Just as bacterial defenses against antibiotics are multipronged, the development of 
ammunition against bacterial pathogens must progress in a multifaceted fashion. The 
regulatory bottleneck for phages has prompted innovations in bactericidal phage products 
such as endolysins (lysins). These are enzymes used by phages to degrade the bacterial 
cell wall for lysis at the end of the lytic cycle. They are classified as peptidoglycan 
hydrolases and lyases that cleave a variety of bonds in the bacterial peptidoglycan (36). 
With few exceptions such as PlySs2 that kills both Streptococcus suis and 
Staphylococcus aureus (37), the target bacteria of each lysin fall within a single genus or 
species. Recombinant lysins against Gram-positive bacteria have been shown to be 
effective bactericidal agents that cause hypotonic lysis (e.g. PlyC against Streptococcus 
spp. (38), PlyG against Bacillus anthracis (39), etc.) Typically, each lysin is made up of 
one or two N-terminal catalytic domains (CD) and a C-terminal cell wall binding domain 
(CWBD) (40), with the notable exception of PlyC, a multimeric enzyme comprised of a 
catalytic PlyCA subunit and a binding PlyCB octamer) (38). Compared to phages, lysins 
present fewer regulatory challenges since cocktails are unnecessary and there is virtually 
no concern for resistance development or spread of antibiotic resistance genes. The 
immunogenicity of lysins is also negligible but inflammatory responses could be 
triggered by dead bacterial components. Overall, lysins are promising antimicrobials 
against Gram-positive bacteria (40). 
In contrast, the Gram-negative counterparts are relatively less active because the 
outer membrane largely limits the accessibility of subjacent peptidoglycan (Figure 1.4). 
Different strategies have been employed to increase the membrane permeability to lysins, 
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including the use of the chelating agent EDTA (41, 42), and the modification of lysins 
with either highly charged/hydrophobic N-/C-terminal extensions (43) or other 
membrane translocating domains (44, 45). The success of each approach varies in terms 
of efficacy increase and clinical applicability.  
Nonetheless, a few naturally active lysins have been identified and characterized, 
e.g. LysAB2 (46) and PlyF307 (47). LysAB2 was isolated from lytic phage ΦAB2 and 
was shown to have bactericidal activities against Streptococcus sanguis, A. baumannii 
and E. coli (46). On the other hand, PlyF307 was identified as the most active lysin 
among those isolated by screening for inducible lysis genes cloned from a genomic 
library of prophages from 13 A. baumannii strains. It was shown to be specifically active 
against A. baumannii and to be able to rescue mice from lethal bacteremia (47). These 
lysins are capable of killing A. baumannii in spite of the outer membrane barrier. Both 
LysAB2 and PlyF307 employ distinct domain structures. Instead of the conventional CD-
CWBD motif, they are composed of an N-terminal lysozyme-like domain and a C-
terminal positively charged peptide (Figure 1.5). The C-terminus of LysAB2 putatively 
forms an amphipathic helix and without it, LysAB2 was shown to lose 40% of its 
bactericidal activity. It has also hypothesized that the positively charged peptide promotes 
the membrane trespassing (46). This project focuses on the characterization of such a 




Figure 1.4 Simplified cell wall structures of Gram-positive and Gram-
negative bacteria.  
Recombinant phage lysins can effectively cleave the exposed peptidoglycan and bring 
about hypotonic lysis in Gram-positive bacteria. In contrast, Gram-negative phage lysins 
have only limited access to their peptidoglycan substrate because of the outer membrane. 
Adapted by permission from Taylor andFrancis Group: Janeway’s Immunobiology, 8th 




 Figure 1.5 Putative conserved domains of LysAB2 and PlyF307. 
According to a National Center for Biotechnology Information Basic Local Alignment 
Search Tool (BLAST) search, both LysAB2 and PlyF307 contain lysozyme-like domains. 
The stars (*) mark the putative amphipathic helix (46) in LysAB2 (amino acids 113-145) 
and the similar region with a high positive charge (+7) in PlyF307 (amino acids 108-
138).
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1.2.3 Antimicrobial peptides 
 Antimicrobial peptides (AMPs) represent an important class of weapons in the 
fight against bacteria. They are ubiquitous in all living organisms and come in different 
sequences and structures, e.g. cationic LL-37 human cathelicidin with an amphipathic α-
helix (49), cysteine-rich pig protegrin-1 with anti-parallel β-strands (50), anionic human 
dermcidin with α-helix that forms hexameric bundle (51), antimicrobial peptide from 
human hepatitis B virus core protein arginine-rich domain (HBc ARD) (52) and so on. 
Like antibiotics, they have varied mechanisms of action, but primarily kill by 
permeabilizing the membrane. While they show great potential for clinical use, AMPs 
also present several safety concerns including toxicity and resistance development. 
Membrane permeabilization by AMPs is usually concentration dependent. Although 
mammalian membranes are spared because of the differences in lipid compositions, the 
selectivity could be nullified at higher doses (53). Similarly, the likelihood is low for 
bacteria to become resistant to AMPs. However, the immune evasion by pathogens could 
be exacerbated if bacteria do develop resistance that is cross reactive to human AMPs, a 
crucial part of innate immunity (54). Even with these safety concerns, a few AMPs are in 
clinical trials for topical applications (53), indicating that AMPs are viable options to 




 The emergence of PDR A. baumannii severely diminishes the treatment options 
for this opportunistic pathogen. With a growing interest in the use of phages, several 
phages that infect A. baumannii have been identified and characterized. However, their 
restricted spectrum (killing only ∼60% of A. baumannii isolates) limits the effectiveness 
of such phages as therapeutic agents (55-57). By comparison, the lysins are active against 
A. baumannii as a species and those with higher bactericidal activities comprise an N-
terminal catalytic domain and a highly positively charged C-terminal peptide (46, 47). 
Considering the atypical domain composition, we tested the hypothesis that the peptide 
contributes to the lysins’ activities by destabilizing the outer and inner membranes. We 
also aim to investigate the applicability of such peptides as AMPs against drug resistant 
A. baumannii.  
 To achieve these objectives, we characterized the positively charged C-terminus 
of A. baumannii phage lysin PlyF307 as P307. We also designed four derivatives and 
performed bactericidal assays to compare their activities. For the most active derivative 
and P307, we determined their minimum inhibitory concentrations (MIC) and synergies 
with antibiotics. After examining their selectivity in permeabilizing membranes, toxicity 
and serum tolerance, we proceeded to study their effectiveness in clearing A. baumannii 
from mouse skin infections. With this study, we aim to demonstrate the prospect of using 
peptide derivatives from lysins as antibacterial agents against Gram-negative pathogens. 
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2 CHAPTER 2 – LYSIN-BASED ANTIMICROBIAL PEPTIDES 
2.1  MATERIALS AND METHODS 
2.1.1  Peptides 
2.1.1.1 Identification, modifications and structural predictions 
Previously published works on phage lysins against Gram-negative bacteria (46, 
47) suggested that the C-terminal portions of the lysins might destabilize the bacterial 
outer membrane to facilitate access to the peptidoglycan which is the lysin’s substrate 
(Figure 2.1). Specifically, the highly cationic C-terminal region of A. baumannii phage 
lysin LysAB2 was speculated to be involved in permeabilizing the outer membrane (46). 
A similar highly positively charged sequence was identified in one of A. baumannii 
phage lysins isolated in our laboratory. This peptide was named P307, and it extends 
from amino acids 108-138 in PlyF307 (47), and resembles the LysAB2 peptide in terms 
of length and charge, but sharing only 41.2% similarity and 17.6% identity (MacVector 
ClustalW alignment).  
P307 was modified with the eight amino acids constituting the full C-terminal part 
of native PlyF307, forming peptide P307AE-8. In addition, eight amino acids 
(SQSRESQC) were fused to the C-terminus of P307 to yield P307SQ-8C. This 
modification was based on the observation of an earlier study showing that the lack of 
these eight amino acids reduces the activity spectrum of the antimicrobial peptide HBc 
ARD (52) against Gram-negative bacteria. Two additional modifications of P307SQ-8C 
were also generated by: scrambling the sequence of the last eight amino acids to 
CSQRQSES (P307CS-8); and changing the last amino acid from C to A (P307SQ-8A). The 
sequence was scrambled to evaluate the importance of a specific sequence and the 
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cysteine change was introduced to examine the importance of intermolecular disulfide 
bond formation for activity. The amino acid sequences of the peptides are summarized in 
Table 2.1.  
The structures of PlyF307 and P307SQ-8C were predicted by I-TASSER server 
(Zhang Lab, University of Michigan) (58-60) and the helical wheel plot for P307SQ-8C 
was created by NetWheels web application (61). 
 
Figure 2.1 Permeabilization of outer membrane by Gram-negative lysin. 
The cluster of positively charged amino acids at the C-terminus has been hypothesized to 
allow the lysin to traverse the outer membrane to reach the peptidoglycan. Upon contact 
with the peptidoglycan, the catalytic domain cleaves specific bonds resulting in hypotonic 
lysis and death.  Adapted by permission from Portland Press: Biochemical Society 
Transactions (62), copyright 2016.  
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Table 2.1 Peptide derivatives of PlyF307 







146 amino acids (GenBank Accession Number KJ740396) 
NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRK (108th-138th) 
NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRKAEMELFLK (original) 




Peptides were synthesized at The Rockefeller University Proteomics Resource 
Center.  All peptides were created using a Protein Technologies Symphony™ peptide 
synthesizer (PTI Tucson, Arizona, USA) on pre-coupled Wang (p-alkoxy-benzyl alcohol) 
resin (Bachem, Torrance, CA, USA). Reaction vessels were loaded at 25 µM and 
peptides were elongated using Fmoc protected amino acids (Anaspec, San Jose, CA, 
USA) (63). Deprotection of the amine was accomplished with 20% piperidine (Sigma-
Aldrich) in NMP (N-methylpyrrolidinone). Repetitive coupling reactions were conducted 
using 0.6 M HATU/Cl-HOBT (azabenzotriazol tetramethyluronium 
hexafluorophosphate/6-chloro-1-hydroxybenzotriazole)(P3 Biosystems, Shelbyville, KY, 
USA) and 0.4 M NMM (N-methylmorpholine) using NMP (EMD) as the primary solvent 
(64). Resin cleavage and side-chain deprotection were achieved by transferring to a 100 
mL round bottom flask and reacted with 4.0 mL concentrated, sequencing grade, 
trifluoracetic acid (Fisher) with triisopropylsilane (Fluka), degassed water, and 3,6-dioxa-
1,8-octanedithiol (DODT, Sigma-Aldrich) in a ratio of 95:2:2:1 over a 6 h time frame. 
This was followed by column filtration to a 50 mL round bottom flask and TFA volume 
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reduced to 2 mL using a rotary evaporator. A standard ether precipitation was performed 
on the individual peptides by transferring to a 50 mL falcon tube containing 40 mL cold 
tert-butyl methyl ether (TBME, Sigma-Aldrich). Samples were placed in an ice bath for 2 
h to aid precipitation followed by pellet formation using centrifugation (3300 rpm, 5 
min). Excess ether was removed by vacuum aspiration and the peptide pellets were 
allowed to dry overnight in a fume hood. Dried peptide pellets were resolved in 20% 
acetonitrile and 10 mL HPLC grade water, subsampled for LC/MS and lyophilized. All 
crude products were subsequently analyzed by reverse-phase Aquity™ UPLC (Waters 
Chromatography, Milford, MA, USA) using a Waters BEH C18 column. Individual 
peptide integrity was verified by tandem electrospray mass spectrometry using a 
ThermoFinnigan LTQ™ (Thermo Fisher, Waltham, MA, USA) spectrometer system. 
Preparative chromatography was accomplished on a Vydac C18 RP preparative column 
on a Waters 600 Prep HPLC. Individual fractions were collected in 30 s intervals, 
characterized using LC/MS and fractions containing desired product were lyophilized. 
These were stored at -20°C until being re-suspended in autoclaved Milli-Q water for 
various assays. The stock solutions were then stored at 4°C. 
2.1.2  Activity 
2.1.2.1 Bacterial strains and growth conditions 
A. baumannii strains in this study include clinical isolates from Hospital for 
Special Surgery in New York (#1775-#1799) (47), Ohio State University (S1, S3 and S5 
provided by Dr. Vijay Pancholi), and ATCC® 17978™ from American Type Culture 
Collection. Bacteria were cultured in Trypticase Soy Broth or Brain Heart Infusion (TSB 
or BHI; Thermo Fisher Scientific, Waltham, MA, USA) at 37°C with aeration (200 rpm). 
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Stationary phase bacteria were cultured overnight while log phase bacteria were grown 
for 3 h in fresh media from 100x dilutions of overnight cultures. Strains for determining 
the specificity of the antimicrobial peptides were cultured under the same conditions, at 
the temperatures indicated: B. anthracis ΔSterne (30°C), E. coli DH5α (37°C), K. 
pneumoniae ATCC® 700603TM and 10031TM (37°C), P. aeruginosa PAO1 (30°C), and S. 
aureus RN4220 (30°C).  
Biofilms were set up as previously described (47). Briefly, an overnight culture of 
A. baumannii strain #1791 was diluted 1000x (~105 cfu/mL) in TSB containing 0.2% 
glucose and incubated at 37°C for 72 h in ~2.5 cm segments of PVC catheter tubing 
(CareFusion) with the ends clamped shut to prevent evaporation. The catheter biofilms 
were washed with autoclaved Milli-Q water to remove planktonic cells before peptide 
treatment. Crystal violet (0.1%) was used to detect the presence of biofilm. 
2.1.2.2 Bactericidal assays 
Unless otherwise indicated, stationary phase bacteria (overnight cultures) were 
used for the assays. Bacteria were washed in assay buffer, re-suspended to ∼106 cfu/mL, 
mixed with each antimicrobial peptide and incubated for 2 h at room temperature (22-
25°C). After treatment, the reactions were serially diluted and plated for enumeration. 
Influencing factors on the activities of the peptides (P307 and P307SQ-8C) were examined: 
buffer (50 mM sodium phosphate or Tris-HCl, pH 6.8-8.8; NaCl (0-200 mM); 
concentration (0-125 µg/mL P307); time (1-120 min); specificity (the bacterial strains 
mentioned above); and growth phase (log, stationary and biofilm). The buffer system for 
the experiments with the latter five factors was 50 mM Tris-HCl, pH 7.5. The biofilm-
associated bacteria were re-suspended by thoroughly scraping the catheter tubing and 
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vortexing for 1 min. Experiments were conducted at least in triplicate and representative 
data are shown as mean + standard deviation. The black horizontal lines mark the limit of 
detection. 
2.1.2.3 MIC, resistance and synergy assays 
The broth microdilution method was used (65) to determine the MICs of 
levofloxacin, ceftazidime, polymyxin B, P307 and P307SQ-8C for A. baumannii strains 
#1791, #1798, S5 and ATCC17978. For the antibiotics, 1.5–2 fold serial dilutions (three 
lower and three higher) of the MICs determined by Etest (47) were included. For the 
peptides, two-fold serial dilutions (2000–31.25 µg/mL) were tested. Overnight cultures 
were re-suspended to ~105 cfu/mL in Mueller Hinton broth (pH 7.9). Antibiotics or 
peptides were added to a final volume of 100 µL for each dilution. Bacteria were allowed 
to grow at 37°C for 24 h at 220 rpm. The absorbance at 595 nm was then read in a 
SpectraMax Plus Reader (Molecular Devices). The MICs were determined as the lowest 
concentrations of antimicrobial agents that visibly inhibited bacterial growth. In addition, 
Alamar®Blue was used to confirm the data obtained from OD595. Each experiment was 
repeated at least twice in duplicate.  
Resistance development was investigated for P307, P307SQ-8C and polymyxin B 
with modifications to a published protocol (37). Briefly, A. baumannii strain #1791 was 
grown in two-fold serial dilutions (0.25× to 2× MIC) of the antimicrobial agents. The 
cultures commenced with 105 cfu/mL in MH broth (pH 7.9) as described above. The next 
day, each thriving culture in the highest concentration well was taken through the process 
again with two-fold serial dilutions (0.25× to 2× MIC) of respective antimicrobial agents 
and 105 cfu/mL starting culture. The process was repeated 7 times. 
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To investigate whether synergy exists between each peptide and antibiotic, 
checkerboard assays were conducted by mixing fractional inhibitory concentrations 
(FICs) of antibiotics (levofloxacin, ceftazidime and polymyxin B) with those of peptides 
P307 and P307SQ-8C as previously described (66). Isobolograms were constructed to 
determine the fractional inhibitory concentration indices (FICIs). Each experiment was 




2.2.1 Structural analyses of peptides 
The predicted structures of PlyF307 and P307SQ-8C suggested that the peptides 
form a “hairpin-like” di-alpha helical structure connected with a flexible linker region 
and the helical wheel plot suggested an amphipathic helix motif (Figure 2.2). 
 
Figure 2.2 Structural analyses. 
Predictions of (A) PlyF307 and (B) P307SQ-8C by I-TASSER server (58-60). (C) Helix 
wheel plot of P307SQ-8C by NetWheels web application (61). 
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2.2.2  Activity 
2.2.2.1 Bactericidal assays 
First the bactericidal activities of the peptides P307, P307AE-8 and P307SQ-8C were 
compared. P307SQ-8C was the most active, reducing ~106 cfu/mL of bacteria to below the 
limit of detection (<10 cfu/mL). P307 was slightly more active than P307AE-8, but both 
peptides induced ~3.8-log decreases in viability (Figure 2.3A). Since P307SQ-8C was the 
most active, the importance of the last eight amino acids SQSRESQC was investigated. 
To test whether the linkage between P307 and the eight-amino-acid peptide was 
important, the activities were compared among P307, P307SQ-8C, the combination of P307 
and equimolar concentrations of the SQSRESQC peptide and the SQSRESQC peptide 
alone. The combination was only as active as P307 while the SQSRESQC peptide alone 
had no activity (Figure 2.3B). Hence the linkage was essential for the high bactericidal 
activity of P307SQ-8C. Next, the importance of sequence and composition was investigated 
by synthesizing P307CS-8 with the last eight amino acids in P307SQ-8C scrambled to 
CSQRQSES. The bactericidal activities of P307SQ-8C and P307CS-8 were comparable 
(Figure 2.3C), indicating that the amino acid composition was more important than the 
sequence for the superior activity of P307SQ-8C. For further investigation, we used P307SQ-
8C since it was the most active, and compared its activity to P307. 
  
 27 
Figure 2.3 Comparison of in vitro 
bactericidal activities of peptides.  
Bacteria were treated with 50 µg/mL 
of each peptide for 2 h at 22-25°C. 
Serial dilutions were plated for cfu 
counting. (A) The bactericidal 
activities of P307 and its variants 
P307AE-8 and P307SQ-8C against A. 
baumannii strains #1791, S5 and 
ATCC17978. (B) The activities of 
P307, P307SQ-8C, and equimolar 
SQSRESQC peptide with and without 
P307 against strains #1791 and S5. 
(C) The activities of P307SQ-8C and a 
scramble variant P307CS-8 against 
strains #1791, S5 and ATCC17978. 
The error bars show standard 
deviation and the black horizontal 
line marks the limit of detection.
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The effects of pH and NaCl on the in vitro activities of P307 and P307SQ-8C were 
investigated. A. baumannii strain #1791 was treated with 50 µg/mL of either peptide in 
the presence of varying pH and salt conditions. Using two buffer systems (sodium 
phosphate and Tris-HCl), pH 6.8, 7.5, 8.0 and 8.8 were compared. The peptides were 
more active in Tris-HCl buffer and higher pH values elicited better killing (Figure 2.4A). 
Thus, the in vitro experiments were continued with 50 mM Tris-HCl, pH 7.5 to 
approximate physiological pH. The activities of both peptides were inversely 
proportional to the concentration of NaCl (Figure 2.4B). When titration and killing 
kinetics were investigated, the activities of both peptides were concentration-dependent 
(Figure 2.4C) and P307SQ-8C acted faster than P307, resulting in ~3.2-log decrease after 5 
min, with a continued reduction in bacterial count up to ~5 logs 120 min after P307SQ-8C 
addition (Figure 2.4D). There was no difference in activities of both peptides either at 
room temperature (22-25°C) or 37°C and they retained activity after being heated at 95ºC 
for 1 h (data not shown). From these in vitro characterization experiments, the optimal 
experimental conditions were chosen to be 50 µg/mL peptides in 50 mM Tris-HCl, pH 




 Figure 2.4 In vitro bactericidal activities of P307 and P307SQ-8C. 
A. baumannii strain #1791 was treated with 50 µg/mL of P307 or P307SQ-8C for 2 h at 22-
25°C to investigate the optimal (A) pH and (B) NaCl concentration for killing. The same 
conditions, except for the variables, were used with 50 mM Tris-HCl, pH 7.5 to 
determine the (C) optimal killing concentration, and (D) killing kinetics. The error bars 
show standard deviation and the black horizontal line marks the limit of detection.
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The in vitro bactericidal spectra of P307 and P307SQ-8C were also examined. 
Among the bacteria tested, A. baumannii strains were consistently the most sensitive to 
the peptides, showing an average of 2.7- and 6.2-log decrease with P307 and P307SQ-8C, 
respectively. Bacillus anthracis, Pseudomonas aeruginosa and Staphylococcus aureus 
were moderately sensitive to P307 and P307SQ-8C, with an average of ~1.3- and 2.9-log 
decrease, respectively. Both E. coli and Klebsiella pneumoniae were resistant to the 
peptides under these experimental conditions (Figure 2.5). 
To examine the activity of each peptide against A. baumannii at different growth 
phases, the sensitivities of strain #1791 were compared at log phase, stationary phase and 
in biofilms. The log phase organisms were slightly more sensitive to P307 than stationary 
phase (~3.7- versus 2.4-log decrease) (Figure 2.6A). However, no such difference was 
observed for P307SQ-8C, with both growth phases being equally sensitive to the maximal 
killing effect of the P307SQ-8C (>5-log decrease). Biofilm-associated A. baumannii was 
more resistant (Figure 2.6B). Biofilms were treated with 250 µg/mL P307 or P307SQ-8C 
for 2 or 24 h. After 2 h, ~3- and 4-log decrease in cfu/mL was observed with P307 and 
P307SQ-8C, respectively. After 24 h, an additional ~1.3-log decrease was observed with 




Figure 2.5 In vitro bactericidal spectra of P307 and P307SQ-8C. 
Different bacterial species (A. baumannii, B. anthracis, E. coli, P. aeruginosa, S. aureus 
and K. pneumoniae) were treated with 50 µg/mL of P307 or P307SQ-8C in 50 mM Tris-
HCl, pH 7.5 for 2 h at 22-25°C to investigate the specificity of the peptides. Serial 
dilutions were plated for cfu counting. The error bars show standard deviation and the 
black horizontal line marks the limit of detection.
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 Figure 2.6 Bactericidal activities of P307 and P307SQ-8C against A. baumannii 
strain #1791 in log phase, late-stationary phase and biofilm. 
(A) Bacteria in log phase and late stationary phase were treated with 50 µg/mL of P307 
or P307SQ-8C for 2 h at 22-25°C. (B) A. baumannii biofilms in PVC catheters were treated 
with 250 µg/mL of P307 or P307SQ-8C for 2 or 24 h at 22-25°C. Serial dilutions were 
plated for cfu counting. The error bars show standard deviation and the black horizontal 
line marks the limit of detection.
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2.2.2.2 MIC, resistance and synergy assays 
In order to compare the efficiency of the peptides with clinically used antibiotics, 
minimal inhibitory concentration (MIC) assays were performed on four A. baumannii 
strains: #1791, #1798, S5 and ATCC17978. The strains displayed varying degrees of 
sensitivity to levofloxacin, ceftazidime and P307 while the MICs of polymyxin B and 
P307SQ-8C were more consistent (Table 2.2). P307SQ-8C had a lower MIC than P307, 
which was in accordance with in vitro killing activity (Figure 2.3 and 2.5). 
No resistance was observed for any of the antimicrobial agents. However since 
the starting culture was 105 cfu/mL, it is likely that the frequency of resistant clone 
development was not high enough to be detected. 
The synergistic effects were examined between each peptide and levofloxacin, 
ceftazidime or polymyxin B by the checkerboard method (isobologram). No synergy was 
observed between either peptide and levofloxacin or ceftazidime (data not shown). 
However, polymyxin B acted synergistically with both P307 and P307SQ-8C (FICIs = 
0.125, <0.5). 
Table 2.2 MIC comparison of peptides and antibiotics examined in this study 
A. baumannii 
strains 
Levofloxacin Ceftazidime Polymyxin B P307 P307SQ-8C 
µg/mL µM µg/mL µM µg/mL µM µg/mL µM µg/mL µM 
#1791 6 16.6 128 234 0.25 0.19 750 221 62.5 14.5 
#1798 32 88.6 >1024 >1873 0.25 0.19 1000 294 62.5 14.5 
S5 6 16.6 64 117 0.25 0.19 2000 588 125 29 
ATCC17978 0.075 0.21 6 11 0.25 0.19 750 221 125 29 
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3 CHAPTER 3 – INFLUENCING FACTORS ON BACTERICIDAL 
ACTIVITIES 
3.1 MATERIALS AND METHODS 
3.1.1 Inter-peptide disulfide bond formation 
The contribution of disulfide bond formation to the increased activity of P307SQ-8C 
was investigated by comparing with P307SQ-8A in the presence of the reducing agent 
TCEP (0.1 and 1 mM) (Tris (2-carboxyethyl) phosphine hydrochloride solution)(Sigma). 
Experiments were conducted at least in triplicate and representative data are shown as 
mean + standard deviation. 
3.1.2 pH-dependent sensitivity of E. coli and K. pneumoniae 
The least sensitive Gram-negative species at pH 7.5 (Figure 2.5) were treated with 
50µg/mL P307 or P307SQ-8C at pH 8.8. Experiments were conducted at least in triplicate 
and representative data are shown as mean + standard deviation. The black horizontal line 
marks the limit of detection. 
3.1.3 DNA-binding assay 
The affinity of peptide P307 for DNA was investigated by electrophoretic 
mobility shift assay (67). P307 was mixed with 50 ng of random DNA (1 kb amplicon of 
Bdellovibrio genomic DNA) at different peptide to DNA ratios (0:1-15:1) in a binding 
buffer (5 mM Tris-HCl, pH 8.0, 10 mM EDTA, 5% glycerol, 20 mM KCl, 50 µg/mL 
BSA). As a positive control, a peptide from Bdellovibrio bacteriovorus that was 
previously found in our laboratory to have DNA-binding capacity (amino acid sequence –  
MASKTKKTEYIRERKKATSGKKRKAANRTKGTTKSAKTLFKD) was used 
 36 
(unpublished results). After incubation for 1 h at 22-25°C, the peptide and DNA mixture 
was analyzed by Agarose gel electrophoresis (67). 
3.1.4 Transmission electron microscopy (TEM) 
An overnight culture of A. baumannii strain #1791 was collected, washed in 50 
mM Tris-HCl, pH 7.5 and re-suspended in the same buffer to ~108 cfu/mL. The bacteria 
were treated with buffer (control) or 300 µg/mL P307SQ-8C or 1 mg/mL lysozyme (from 
chicken egg white, lyophilized powder, protein ≥90%) (Sigma) or 300 µg/mL P307SQ-8C 
and 1 mg/mL lysozyme combined for 5 min or 2 h. The samples were fixed with 2.5% 
glyceraldehyde in 0.1 M sodium cacodylate, and then TEM images were taken at 
magnification ×3300 or ×6600. Representative figures are shown. 
3.1.5 SYTOX green uptake assay 
The permeability of bacterial membrane upon peptide treatment was measured by 
SYTOX® Green uptake (52). Briefly, overnight cultures of bacteria were washed and re-
suspended to ∼107 cfu/mL in 50 mM Tris-HCl pH 7.5. Benzonase® nuclease (25 
U/mL)(Novagen) and SYTOX® Green (1 µM)(Invitrogen) was added to the bacterial 
cells, and incubated for 15 min at 22-25°C in the dark. Peptides (50 µg/mL; 14.7 µM 
P307 and 11.6 µM P307SQ-8C) were added. Polymyxin B (2 µg/mL)(Sigma) was used as a 
control (68). Relative fluorescence units (RFU) were measured in a SpectraMax Plus 
reader (Molecular Devices) at 22-25°C (ex: 485 nm, em: 520 nm) for 2 h. Experiments 




3.2  RESULTS 
3.2.1 Inter-peptide disulfide bond formation 
Since P307SQ-8C contained a C-terminal cysteine, the importance of disulfide bond 
formation for the high activity of P307SQ-8C was investigated. SDS-PAGE analysis 
showed that a portion of P307SQ-8C (~5-10%) ran at twice the theoretical molecular 
weight (MW) of this peptide while all of P307SQ-8A ran at the theoretical MW (data not 
shown), suggesting a role for disulfide bond formation. To examine this, the C-terminal 
cysteine residue of P307SQ-8C (the only cysteine in this peptide) was changed to alanine. 
The resulting alanine variant, P307SQ-8A, ran at the expected size for a peptide monomer 
(4.3 kDa) with no observable band at the dimer location by SDS-PAGE (data not shown). 
The difference in bactericidal activities of P307SQ-8A and P307SQ-8C were compared within 
the limit of detection by using 10 µg/mL peptides instead of 50 µg/mL. Furthermore, 
TCEP (0.1 and 1 mM) was added to specifically reduce disulfide bonds. Without TCEP, 
P307SQ-8C was more active than P307SQ-8A (~5- versus ~2.7-log decrease) (Figure 3.1). 
The addition of TCEP did not affect P307SQ-8A while the activity of P307SQ-8C was 
reduced by ~2 logs. However, P307SQ-8A was still more active than P307, suggesting that 
although disulfide bond formation was important, it was not the only contributing factor 
for the superior activity of P307SQ-8C. 
3.2.2 pH-dependent sensitivity of E. coli and K. pneumoniae 
Among the Gram-negative species examined, E. coli and K. pneumoniae were the 
least sensitive to the peptides at pH 7.5 (Figure 2.5). However, at pH 8.8, both were 
sensitive to 50 µg/mL of the peptides (Figure 3.2), indicating the electrostatic interactions 
between the peptides and bacterial membrane. 
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 Figure 3.1 The importance of terminal cysteine and its disulfide bond 
formation for bactericidal activity of P307SQ-8C. 
A. baumannii strain #1791 was treated with 10 µg/mL P307SQ-8A (with Ala instead of Cys 
at the C-terminus) or P307SQ-8C in 50 mM Tris-HCl, pH 7.5 with or without TCEP for 2 h 





 Figure 3.2 Bactericidal activities of P307 and P307SQ-8C against K. 
pneumoniae and E. coli at pH 7.5 and 8.8. 
The bacteria were treated with 50 µg/mL peptides in 50 mM Tris-HCl for 2 h at 22-25°C. 
Serial dilutions were plated for cfu counting. The error bars show standard deviation and 
the black horizontal line marks the limit of detection.
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3.2.3 DNA-binding assay 
Due to the presence of several cationic residues on the peptides (net charge of 
+7), their effects on DNA were investigated. The affinity of P307 for DNA was 
examined by electrophoretic mobility shift assay. There was no shift in molecular weight 
at all ratios of P307 to DNA tested whereas a positive control peptide known to bind 
DNA caused a clear shift in electrophoretic mobility (Figure 3.3). 
 
 Figure 3.3 Affinity of P307 for DNA. 
The peptide P307 was mixed with DNA at different peptide:DNA ratios (0:1-15:1) and 
incubated for 1 h before being analyzed on an Agarose gel. In comparison to positive 
control peptide, no electrophoretic shift was observed for P307. 
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3.2.4 Transmission electron microscopy (TEM) 
Another negatively charged bacterial component investigated was bacterial 
membrane. TEM was used to visualize the effects of P307SQ-8C on A. baumannii 
membrane. The samples were prepared by treating A. baumannii strain #1791 with buffer 
(control) or 300 µg/mL P307SQ-8C or 1 mg/mL lysozyme or peptide and lysozyme 
combined for 5 min or 2 h. A comparison of the TEM images revealed that treatment 
with P307SQ-8C led to: 1) membrane blebbing and changes in intracellular density, 2) 
appearance of ‘intact bacterial ghosts’, and 3) occasional disruption of the cell wall and 
cytoplasmic membrane (Figure 3.4A, B and C). On the other hand, lysozyme hydrolyzed 
the peptidoglycan and released the cellular content (Figure 3.4D). Finally, the combined 
treatment resulted in complete debris formation as P307SQ-8C and lysozyme destabilized 
the membrane and peptidoglycan simultaneously (Figure 3.4 E and F). 
3.2.5 SYTOX green uptake assay 
As our data suggested a killing mechanism by cytoplasmic membrane 
destabilization, the extent of bacterial membrane disruption by P307 and P307SQ-8C was 
measured using the SYTOX® Green uptake assay. Both peptides permeabilized the 
membranes of A. baumannii strain #1791 at pH 7.5 and K. pneumoniae strain 
ATCC700603 at pH 8.8, giving rise to an increase in fluorescent signals of SYTOX® 
Green dye as it bound to intracellular DNA. In contrast, the signal increase was minimal 
for K. pneumoniae ATCC700603 at pH 7.5 (Figure 3.5). The results were consistent with 




Figure 3.4 Representative TEM images. 
A. baumanii strain #1791: untreated control (A), treated with 300 µg/mL P307SQ-8C for 5 
min (B) and for 2 h (C), treated with 1 mg/mL lysozyme for 2 h (D), treated with 300 
µg/mL P307SQ-8C and 1 mg/mL lysozyme for 5 min (E) and for 2 h (F). Magnification, ×
3300 (left, scale bar = 1 µm) and ×6600 (right top and bottom, scale bar = 600 nm). 
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Figure 3.5 Membrane permeability of bacteria treated with P307 and P307SQ-
8C. 
A. baumannii strains #1791 and K. pneumoniae strain ATCC700603 were treated in 50 
mM Tris-HCl at indicated pH with 50 µg/mL of P307 or P307SQ-8C in the presence of 1 
µM SYTOX® Green (Invitrogen). Benzonase® nuclease (25 U/mL)(Novagen) was also 
added to remove extracellular DNA. The permeability of bacterial membrane was 
monitored for 2 h by the increase in relative fluorescence units of SYTOX® Green dye, 
using polymyxin B as a positive control. The error bars show standard deviation. 
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4 CHAPTER 4 – SAFETY AND IN VIVO ACTIVITY 
4.1 MATERIALS AND METHODS 
4.1.1 Cytotoxicity assays 
The hemolytic assays were conducted as previously described (52). Briefly, 
human blood was gathered in an EDTA-tube, and red blood cells (RBC) were collected 
through low speed centrifugation. Cells were washed and re-suspended to a 10% RBC 
solution in PBS, and mixed with 80 µM (345 µg/mL) P307SQ-8C. PBS and 1% Triton X-
100 were used as negative and positive controls, respectively. After 1 h incubation at 
37°C, the supernatant was collected, and the absorbance at 405 nm was recorded through 
SpectraMax Plus Reader (Molecular Devices) to measure the release of hemoglobin. The 
reactions were carried out twice in triplicate and representative data are shown as mean + 
standard deviation. 
A human B lymphoblastoid cell line (LCL) obtained from The Rockefeller 
University was grown in RPMI media supplemented with L-glutamine and 10% fetal 
bovine serum. Cells were harvested by low speed centrifugation, washed and re-
suspended in PBS to ~5x106 live cells/mL, as determined by trypan blue exclusion tests. 
LCL cells (~5x105) were incubated with 40, 80 and 120 µM P307SQ-8C at 37°C in a 
humidified 5% CO2 atmosphere for one hour. The cells were then stained according to 
manufacturer’s instructions (CellTiter 96 Non-radioactive cell proliferation assay, 
Promega) where live B cells reduced the dye to insoluble formazan for an additional 4 h. 
Solubilization/Stop solution was added and incubated at 37°C overnight. Next, the 
absorbance at 570 nm was measured in SpectraMax Plus Reader (Molecular Devices) to 
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quantitate B cell survival. Triton X-100 was used as a positive control. The reactions 
were carried out in triplicate and data are shown as mean + standard deviation. 
4.1.2 Endotoxin assay 
 To detect the amount of endotoxin release, strain #1791 (~107 cfu/mL) was 
incubated at 22-25°C for 2 h with different concentrations of P307 or P307SQ-8C. The 
samples were briefly centrifuged (2000 × g) for 1 min to remove live cells. All reagents 
were prepared in endotoxin-free autoclaved Milli-Q water. Endpoint Chromogenic LAL 
Assay (Lonza) was conducted according to manufacturer’s instructions. Polymyxin B and 
100% ethanol were used for comparison and positive control, respectively. The 
experiment was conducted twice in duplicate and representative data are shown as mean 
+ standard deviation. 
4.1.3 Bactericidal activity in plasma and its components 
Human blood was collected in a heparin-tube and centrifuged. The supernatant 
was filtered and stored at 4°C overnight. The filtrate was centrifuged and filtered again to 
remove any debris. The resulting solution was used as 100% plasma. The components of 
plasma examined for interference were monovalent cation (Na+), divalent cations (Ca2+ 
and Mg2+) and albumin. Chloride salts of the cations and albumin from human serum 
(lyophilized powder, ≥ 97%)(Sigma) were prepared in Milli-Q water and sterile filtered. 
Bactericidal assays, as described above, were conducted in 100% plasma, and in buffered 
solutions (50 mM Tris-HCl, pH 7.5) containing 150 mM NaCl, 1 mM CaCl2, 1 mM 
MgCl2, and 50 mg/mL human serum albumin (HSA), using 100 µg/mL P307 or P307SQ-
8C. The experiments were conducted at least in triplicate and data are shown as mean + 
standard deviation. 
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4.1.4 Mouse skin infection 
The Rockefeller University institutional animal care and use committee approved 
all in vivo protocols. Skin infection was induced with A. baumannii as previously 
described (69). Briefly, the backs of 30 female CD-1 mice (6 to 8 weeks of age; Charles 
River Laboratories) were shaved with an electric razor. NairTM depilatory cream was 
applied to the shaved areas to remove any remaining hair. The areas were then 
disinfected with alcohol wipes, and tape stripped with autoclave tape 20 times in 
succession, using a fresh piece of tape each time. The tape stripped areas were disinfected 
again with alcohol wipes. An area of ~ 1 cm2 was then marked and infected with 10 µL 
of ~108 cfu/mL A. baumannii strain #1791. The bacteria were allowed to colonize for 16-
18 h, after which the infected area was either left untreated or treated with 200 µg of 
P307SQ-8C or 2 µg of polymyxin B in autoclaved Milli-Q water for 2 h. To harvest the 
remaining bacteria on the skin, the mice were sacrificed and the infected skin was 
processed in 500 µL PBS for 1-2 min in a Stomacher® 80 Biomaster using a microbag 
(Seward Ltd., UK). The solution was serially diluted and plated on LB agar containing 4 
µg/mL levofloxacin and 12 µg/mL ampicillin for selection. The resulting cfu/mL from 
each animal was plotted as an individual point and the horizontal bars represent the mean 
values. Data were analyzed using Ordinary one-way ANOVA in GraphPad Prism 6.0. 




4.2.1 Cytotoxicity assays 
 Since membrane-acting antimicrobial peptides have been shown to be active 
against mammalian membranes (70), the cytotoxicity of the peptides were evaluated 
using human red blood cells (RBCs) and B cells. In contrast to the 1% Triton-X-100 
positive control, 80 µM (345 µg/mL) P307SQ-8C did not lyse RBCs but killed A. 
baumannii strain #1791 (~4.8 logs) in PBS (Figure 4.1A). Similarly, the survival of B 
cells was not significantly affected by 40, 80 and 120 µM P307SQ-8C (Figure 4.1B). 
4.2.2 Endotoxin assay 
Even though the peptides did not display cytotoxicity against human RBCs, 
toxicity could possibly arise from the bacterial endotoxin released upon peptide 
treatment. Hence, the Endpoint Chromogenic LAL Assay (Lonza) was conducted to 
measure the amount of endotoxin released by A. baumannii strain #1791 after 2 h of 
incubation with peptides. The peptides generated endotoxin unit concentrations similar to 
that of the 100% ethanol positive control. Polymyxin B released more endotoxin at 0.5 
µg/mL than at 2 µg/mL, but less than the peptides (Figure 4.2). This apparent reduced 
release was likely due to the known interaction of polymyxin B with lipid A (71), the 
active component for LAL assay. The peptides did not interfere with endotoxin detection 




Figure 4.1 Cytotoxicity assays. 
(A) Hemolysis. Red blood cells (RBCs) were incubated with 345 µg/mL P307SQ-8C in 
PBS and the release of hemoglobin into the supernatant was measured by OD405 to 
determine hemolysis, using 1% Triton X-100 as a positive control. The activity of 
P307SQ-8C was examined against A. baumannii strain #1791 under the same experimental 
conditions. (B) B cell survival. Live B cells (~5x105) were incubated with 172.5, 345 and 
517.5 µg/mL P307SQ-8C for 1 h at 37°C in a humidified 5% CO2 atmosphere. CellTiter 
96® Non-Radioactive Cell Proliferation Assay (Promega) was conducted to quantify the 
survival of B cells, using 1% Triton X-100 as a positive control. The error bars show 
standard deviation and the black horizontal line marks the limit of detection for cfu/mL.
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Figure 4.2 Endotoxin release. 
A. baumannii strain #1791 (~107 cfu/mL) was treated with different concentrations of 
antibacterials for 2 h at 22-25°C. The samples were centrifuged to remove live cells. The 
supernatant was analyzed with the Endpoint Chromogenic LAL Assay (Lonza) to 
measure endotoxin units, using 100% ethanol as a positive control. The error bars show 
standard deviation and the black horizontal line marks the limit of detection for cfu/mL. 
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4.2.3 Bactericidal activity in plasma and its components 
The activities of the peptides were examined in human blood plasma. Both P307 
and P307SQ-8C (100 µg/mL) were inactive in 100% plasma. The activities in Tris buffer 
were also interfered to varying degrees by the addition of monovalent and divalent 
cations as well as human serum albumin at physiological concentrations (Figure 4.3). 
4.2.4 Mouse skin infection 
Since blood plasma interfered with the activities of both peptides, and the skin is a 
common route of infection by A. baumannii, the in vivo activity of P307SQ-8C was 
investigated using a mouse skin infection model. Skin abrasions were induced on the 
shaved backs of the mice by tape-stripping, and the irritated skin was infected with 106 
cfu of A. baumannii strain #1791 for 16 h. The infected area was then treated with 2 µg 
polymyxin B or 200 µg P307SQ-8C for 2 h after which the infected skin was excised and 
processed for bacterial counts. Both treatments were found to significantly reduce the 
bacterial load (~2 logs) in the infected skin using this single dose (P < 0.02, Ordinary 




 Figure 4.3 Activities of peptides in plasma and its components. 
A. baumannii strain #1791 was treated with 50 µg/mL P307 or P307SQ-8C for 2 h at 22-
25°C in 100% plasma or indicated concentrations of chloride salts of sodium, calcium 
and magnesium and human serum albumin in 50 mM Tris-HCl, pH 7.5. Serial dilutions 
were plated for cfu counting. The error bars show standard deviation and the black 
horizontal lines mark the limit of detection for cfu/mL.
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Figure 4.4 In vivo activity of P307SQ-8C versus that of polymyxin B on tape-
stripped mice infected with A. baumannii strain #1791. 
Topical treatments included no treatment (negative control), 2 µg polymyxin B (1.5 
nmol) and 200 µg P307SQ-8C (46.5 nmol) for 2 h. The bars show the mean values and 
each dot represents one mouse. Statistically significant differences were noted for the 
comparison pairs: negative control and polymyxin B (P = 0.0148) and negative control 
and P307SQ-8C (P = 0.0157), with ~2-log-drop in A. baumannii by each treatment 
(Ordinary one-way ANOVA, Multiple comparisons, Uncorrected Fisher’s LSD test). The 
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5 CHAPTER 5 – DISCUSSION 
5.1 Lysin-based antimicrobial peptides 
5.1.1 Sequence and structure 
 The antimicrobial peptides in this study (Table 2.1) were designed by observing 
the ‘activity-contributing’ parts of phage lysins PlyF307 (47) and LysAB2 (46) and an 
antimicrobial peptide HBc ARD (52). PlyF307 was found to be the most active among 
the 21 distinct lysins isolated by screening a genomic library of prophages that were 
induced from 13 A. baumannii strains. Instead of the domain structures typical of lysins, 
PlyF307 comprises a single lysozyme domain and a C-terminus that has unusually high 
positive net charge (+7). The amino acids 108-138 of PlyF307 are also 41.2% similar and 
17.6% identical to the amino acids 113-145 of LysAB2. In LysAB2, those amino acids 
are essential and their deletion leads to 40% activity loss although they do not encompass 
the active site of the enzyme. Considering the high activity of PlyF307, we synthesized 
the 31 amino acids of PlyF307 as peptide P307 to investigate its stand-alone bactericidal 
activity. In HBc ARD, the removal of the last 8 amino acids (SQSRESQC) diminishes its 
activity against S. aureus. In the hope of enhancing P307 activity, P307SQ-8C was 
designed by piecing together P307 and SQSRESQC. Lastly, P307AE-8 was constructed to 
compare the original extension AEMELFLK of PlyF307 to P307SQ-8C extension. 
 The structural predictions (58-60) of PlyF307 and P307SQ-8C revealed double 
parallel helices joined by a loop for both P307AE-8 and P307SQ-8C. P307 was just a turn 
and a half shorter. And the helices were amphipathic in nature according to the helical 
wheel plot (61) (Figure 2.2). However, when the activities were compared, P307 and 
P307AE-8 had similar activities while P307SQ-8C with its polar amino acids showed the 
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highest bactericidal activity of all (Figure 2.3A). The addition of P307 and SQ-8C 
extension separately did not achieve the same result as P307SQ-8C (Figure 2.3B) and the 
extension by itself was inert. But scrambling the sequence to CSQRQSES in P307CS-8 did 
not affect the bactericidal activity (Figure 2.3C). Although we tested only 1 out of 40,320 
permutations, comparable killing activities by P307SQ-8C and P307CS-8 did suggest that the 
8 amino acids could be arranged in an alternate order. 
5.1.2 In vitro activity 
 The in vitro activity assays of P307 and P307SQ-8C were conducted with clinical 
isolates to examine their antibacterial potential. Bactericidal assays showed that the 
peptides are more active at higher pH (Figure 2.4A) and that P307SQ-8C acted faster than 
P307, easily achieving >6-log-kill in 90 min (Figure 2.4D). They were specific to A. 
baumannii with slight activities against B. anthracis, S. aureus and P. aeruginosa and no 
activity against E. coli or K. pneumoniae at pH 7.5 (Figure 2.5). This selectivity towards 
A. baumannii at pH 7.5 suggests that the outer layers of A. baumannii are more 
negatively charged than those of the other bacterial species included in the assay since at 
pH 8.8, the selectivity is nullified. They were also capable of killing biofilm-associated A. 
baumannii albeit requiring higher concentrations (Figure 2.6B). However, their MICs 
were much higher than that of polymyxin B (Table 2.2). It is possibly due to the 
interference of cations in the growth media. More experimental data are required to 
determine their susceptibility breakpoints, e.g. pharmacokinetics and pharmacodynamics 
(72). Nevertheless, P307SQ-8C could be put to use for decontamination in clinical settings 
because of its fast acting and biofilm killing properties. Since medical equipment and 
furniture are important hospital reservoirs of A. baumannii (15, 16), P307SQ-8C could be 
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used on these surfaces for quick bacterial removal. Moreover, catheter- and ventilator-
associated diseases are caused by the persistence of A. baumannii as biofilms (73), they 
could be prevented by lining the surfaces with P307SQ-8C. 
5.2 Mechanism of action 
Biochemical characterizations of peptides-bacteria interactions have indicated the 
target site to be the outer and inner membranes of A. baumannii. Higher pH in Tris buffer 
elicited better killing activities of the peptides while higher salt concentrations lessened 
their effectiveness (Figure 2.4A and B). Since Tris is a chemical substance known to 
permeabilize membranes (74), it is not surprising that the peptides’ activities were higher 
in Tris buffer than in phosphate buffer. However, it is notable that higher pH and fewer 
cations promote killing. Even E. coli and K. pneumoniae that were resistant to the 
peptides at pH 7.5 became susceptible to killing at pH 8.8 (Figure 3.2). Since the 
theoretical isoelectric points of P307 and P307SQ-8C are 10.70 and 10.38, respectively, 
their net charges should not alter at pH 7.5 and pH 8.8. Possibly the changes occur on the 
bacterial membranes. In Gram-negative bacteria, the outer leaflet of the outer membrane, 
being largely composed of polyanionic LPS, is stabilized by divalent cations (Ca2+ and 
Mg2+) (75). At higher pH and lower salt concentrations, the positively charged peptides 
could more easily establish ionic interactions with the outer membrane to permeate the 
membranes and induce killing. 
Further evidence by synergy, TEM and SYTOX green uptake assays also 
supported the membrane permeabilization as the peptides’ mechanism of action. First, the 
peptides exhibited in vitro synergy with polymyxin B whose membrane target is lipid A 
of LPS (71). Among different possible mechanisms of synergy (76), the most likely 
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scenario is the complementary actions from having the same target, i.e. both the 
polymyxin B and the peptides killed the bacteria by permeabilizing the membrane in a 
way that enhanced each other’s activity. The lack of synergy with levofloxacin and 
ceftazidime suggested that DNA and cell wall were not the targets of the peptides. 
Indeed, the DNA-binding assay showed that P307 did not bind to DNA (Figure 3.3). 
Next, TEM images of A. baumannii treated with P307SQ-8C showed mostly intact bacterial 
‘ghosts’ with altered cytoplasmic content (Figure 3.4B and C) as if the cytoplasm had 
leaked out of the bacteria through the tiny holes punched by the peptide. In contrast, more 
bacterial debris was formed by lysozyme that targets the peptidoglycan (Figure 3.4D). 
During P307SQ-8C killing, the permeabilization of the inner membrane seemed to be the 
limiting step because combined treatment with P307SQ-8C and lysozyme resulted in more 
extensive debris formation. The outer membrane disruption of P307SQ-8C provided the 
lysozyme access to the peptidoglycan and the lysozyme action preceded the inner 
membrane disruption of P307SQ-8C. Lastly, the results from SYTOX green uptake assay 
(Figure 3.5) confirmed that both outer and inner membranes were compromised by the 
peptides to allow the inflow of SYTOX green dye. 
However, the ability of the peptides to permeabilize bacterial membranes raises 
the question of how their parent phage lysin PlyF307 is regulated by the phage during the 
lytic cycle. The regulation of phage lysin is necessary to prevent pre-mature lysis of 
bacteria before the production of phage progeny. Thus, there must be mechanisms in 
place to prevent the positively charged region of PlyF307 disrupting the cytoplasmic 
membrane from within the cell before the progeny are assembled. The peptide region 
might be inhibited by structural conformation or temporal regulation or the non-optimal 
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pH and salt conditions of the cellular environment. Future experiments with the phage 
from which PlyF307 was isolated are necessary to clarify the regulation of PlyF307. 
5.3 In vivo activity 
 The safety and efficacy of the peptides were investigated by hemolysis, 
cytotoxicity, limulus amebocyte lysate (LAL) and plasma interference assays. First, the 
hemolysis and B cell toxicity assays showed that the peptides did not lyse human red 
blood cells and B cells. Although the peptides killed the bacteria by permeabilizing the 
membranes, the mammalian membranes were spared. The cells remained viable at ~500 
µg/mL of P307SQ-8C (Figure 4.1). Next, the LAL assay showed that the peptides released 
endotoxins upon killing the bacteria. The amount released by P307SQ-8C was ~40 times 
higher than that by polymyxin B (Figure 4.2) since the latter binds to lipid A and lowers 
the level of detection. The released endotoxins could potentially initiate undesirable 
inflammatory responses. Lastly, the bactericidal assay in plasma showed that the killing 
activities of the peptides were interfered by plasma and its components such as 
monovalent and divalent cations and serum albumin. The endotoxin release and plasma 
interference together indicated that prophylactic use might not be feasible. Thus, mouse 
skin infection model was selected to investigate the in vivo activity of P307SQ-8C. Using 
200 µg of P307SQ-8C in distilled water, A. baumannii bacterial load on the irritated skin 
surface was significantly reduced (~2-log-drop) (Figure 4.4), indicating that P307SQ-8C 
could be used in topical applications. 
5.4 Opportunities for improvement 
Resistance development was not observed when selecting from 105 cfu/mL. Due 
to material limitations, resistance evolutions at low frequency were not detected. 
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Alternative experiments need to be conducted to better understand the potential of A. 
baumannii developing resistance. For example, the MICs for colistin-resistant clones 
should be determined and compared with non-resistant clones since colistin also 
permeabilizes the membranes to kill the bacteria. Another option is to mutagenize A. 
baumannii and screen for resistant clones. 
 Moreover, there are rooms for further development to achieve higher in vivo 
activities even though the peptides are highly effective at killing A. baumannii in vitro. 
Since disulfide bond formation contributes to the high activity of P307SQ-8C (Figure 3.1) 
and only ~5-10% of the molecules are dimers, P307SQ-8C that forms permanent dimers 
(e.g. with C-C bond in place of S-S bond between cysteines) might be designed by 
incorporating unnatural amino acids. By changing the S-S bond to C-C bond, the 
importance of disulfide bond formation versus that of dimer formation can also be 
differentiated. For example, taking advantage of the peptides’ preference for high pH, 
alkaline excipients can be used to achieve higher killing effect. However, a fine balance 
needs to be maintained for high activity versus alkaline toxicity. Moreover, peptides can 
be further engineered to be active in plasma. By using x-ray crystallography or NMR, 
residues that interact with serum albumin can be deciphered and altered to minimize the 
amount of peptides binding to the most abundant protein in plasma. The challenge in this 
case is to achieve the goal without compromising the activity. Other strategies to improve 
bioavailability include fusing P307SQ-8C to an antibody FC fragment (77) and creating 
‘structurally nanoengineered antimicrobial peptide polymers’ (SNAPPs) (78) with 
P307SQ-8C. By increasing the effective size of the peptide by FC fusion, the adsorption to 
serum albumin could be reduced and FC fragment tag can also be recognized by FC 
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receptors on immune cells. The bulkiness, however, can sterically interfere with the 
peptide’s traversing the outer membrane to destabilize the inner membrane. Last, but not 
least, SNAPPs are star-shaped polymers with multi-functional initiator poly(amidoamine) 
PAMAM core that has 16 or 32 primary amines onto which antimicrobial peptides 
(AMPs) are attached. The original version of SNAPPs with AMPs made up of poly lysine 
and valine killed Gram-negative bacteria indiscriminately and had slight cytotoxic effects 
at high concentrations. The efficacy was retained in the presence of serum despite 
aggregate formation (78). Creating SNAPPs with P307SQ-8C can potentially increase the 
in vivo activity of P307SQ-8C by effectively increasing the local concentrations 16 to 32 
folds. In contrast to the original SNAPPs, P307SQ-8C SNAPPs might be more specific to 
A. baumannii and less toxic to mammalian cells. 
5.5 Potential practical uses 
 The pH dependence and salt intolerance might prevent broad in vivo application 
but skin infections could be treated topically with the peptides. In addition, they could be 
used in hospitals to decontaminate abiotic surfaces and eliminate reservoirs to prevent 
future outbreaks as mentioned above. 
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6 CHAPTER 6 – CONCLUSION 
Due to the notable antibiotic resistance mechanisms of A. baumannii (29), 
membrane-acting drugs like polymyxin B and colistin, with toxic side effects and rising 
resistance, are now the last resort drugs (27). To address the A. baumannii threat, several 
groups have evaluated the use of bacteriophage endolysins to kill multidrug-resistant A. 
baumannii (42, 46, 47). It has been hypothesized that the innate bactericidal activities of 
some of these lysins stem from the permeabilization of the bacterial outer membrane by 
the highly positively charged C-terminal portions (46, 47). In this study, we showed that 
P307, a C-terminal-based peptide from PlyF307 (47), by itself, had high in vitro 
bactericidal activity (Figure 2.3A). Furthermore, we demonstrated that P307 could be 
further engineered for log-fold increased activity. Compared to P307, or  P307AE-8 with 
the eight amino acids (AEMELFLK) constituting the full C-terminal part of native 
PlyF307 (Table 2.1), the modified peptide P307SQ-8C with polar amino acids 
(SQSRESQC) at the C-terminus was 10-15 times more active (Figure 2.5 and Table 2.2). 
Comparison of P307SQ-8C to the scrambled P307CS-8 revealed that the 6 neutral and 2 
charged polar amino acids (SQSRESQC) could be added in an alternate order for similar 
activity (Figure 2.3C).  Thus, while both AEMELFLK and SQSRESQC complete the 
length of the alpha helix to correspond to the adjacent helix in the hairpin structure 
(Figure 2.2), it is the characteristics of the amino acids in the SQSRESQC sequence (not 
the structure) that dictate the increase in activity. 
Both P307 and P307SQ-8C displayed high in vitro bactericidal activities. Not only 
were they effective against numerous clinical isolates of A. baumannii (Figure 2.5) but 
they also killed bacteria in biofilms on the surface of catheters (Figure 2.6B). Since the 
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success of A. baumannii as an opportunistic pathogen is attributed to its improved 
survival through biofilm formation and persistence in hospital environments (79), the 
ability of the peptides to kill biofilm-associated bacteria could be harnessed to disinfect 
hospital environments as well as to eliminate A. baumannii from the lumens of catheters 
in situ. While the in vivo utility of the peptides might be limited due to the diminished 
activity in plasma, the peptides could still be useful on abiotic surfaces such as coatings 
for ventilators and catheters. 
To further increase the potency of the peptides, we analyzed the mechanism of 
action by various in vitro characterizations. The peptides were more active in higher pH 
but did not tolerate salinity. E. coli and K. pneumoniae were resistant to the peptides at 
pH 7.5 but were susceptible at pH 8.8 (Figure 2.5 and 3.2). Since the charges on the 
peptide were not expected to vary as the pH changed from 7.5 to 8.8, we reasoned that 
the changes likely occurred on the bacterial membrane. At higher pH, the bacterial 
membrane can lose its cations, allowing the positively charged peptides to establish ionic 
interactions to disrupt the membrane integrity. Based on these observations and data, we 
postulate the following mechanism of action (Figure 6.1): P307SQ-8C establishes ionic 
interactions with the bacterial outer and inner membranes, traversing the peptidoglycan 
with its small size (4.3 kDa). In the process, the peptide disrupts both membranes (as 
suggested by endotoxin release assay and shown by TEM images and SYTOX® Green 
uptake assay) killing the cell. Assay with TCEP and P307SQ-8A also suggested that the 
bactericidal activity was higher (by ~2-logs) when P307SQ-8C was dimerized. With this 
knowledge base, we are currently exploring additional engineering strategies to further 
improve both PlyF307 and P307SQ-8C. 
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 Figure 6.1 Proposed mechanisms of action. 
When added externally the positively charged peptide P307SQ-8C disrupts the outer 
membrane and traverses the peptidoglycan because of its small size.  The peptide will 
then disrupt the cytoplasmic membrane, resulting in hypotonic lysis and bacterial death. 
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Nosocomial A. baumannii infections of deep wounds, burns and bone or bone 
marrow are highly prevalent and the isolates are often multidrug resistant (17). Since one 
of the common infection routes of A. baumannii is through damaged skin, we utilized an 
already established skin infection model (69) for our in vivo characterization of P307SQ-
8C. The backs of the mice were shaved and tape-stripped to create skin irritations, which 
were then inoculated with 106 cfu of A. baumannii strain #1791. After 16 h of infection, 
mice were topically treated with a single dose of 46.5 nmol P307SQ-8C or 1.5 nmol 
polymyxin B. Both treatments significantly lowered the bacterial burden (~2-log 
decrease) in the skin (Figure 4.4).  
In conclusion, we engineered the positively charged C-terminal peptide P307 
from the A. baumannii phage lysin PlyF307 for improved bactericidal activity. The 
peptides exhibited high in vitro activities, and thus could potentially be utilized to control 
A. baumannii on abiotic surfaces. The target of the peptides appeared to be the bacterial 
membrane and the interaction likely occurred through electrostatic forces. Despite the 
membrane target, the peptides did not lyse or kill human red blood cells and B cells. 
Although body fluids and cations interfered with the activities of the peptides, P307SQ-8C 
significantly decreased the bacterial cell count in a murine skin infection by A. 
baumannii. We are currently investigating different designs to improve the activities of 
the peptides as well as other phage lysins against A. baumannii. 
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7 APPENDIX 
7.1 Interesting observations 
7.1.1 Anaerobic environment decreased bactericidal activities of P307 and P307SQ-8C 
 While investigating the peptides’ mechanisms of action, bactericidal experiments 
were conducted in an anaerobic chamber to investigate the effect of oxygen. A. 
baumannii strain #1791 was washed with and re-suspended in 50 mM Tris-HCl (pH 7.5 
or pH 8.8) and treated with 50 or 200 µg/mL of P307 or P307SQ-8C at 37°C for 2 h 
aerobically or anaerobically. Then the bacteria were serially diluted and plated on TSB 
agar in respective oxygen environments. Afterwards the plates were incubated 
aerobically since A. baumannii is strictly aerobic. 
The bacteria became insensitive to the peptides at pH 7.5 and increasing the pH to 
8.8 restored the sensitivities (Figure 7.1). The experiments were conducted twice in 
triplicate. These results indicated that oxygen is necessary at lower pH to kill the bacteria 
while at high pH, ionic interactions between peptides and membranes are strong enough 
to kill the bacteria by disrupting the membranes without the need for oxygen. The oxygen 
requirement at lower pH is interesting because it has been previously argued that 
bacterial cell death by bactericidal antibiotics induced reactive oxygen species (ROS) (80, 
81) and apoptotic pathway (82). Refuting these arguments, other research groups stated 
that bacterial cell death induced by antibiotics does not depend on ROS formation, ROS 
being the by-product of stress response (83, 84). Peptides requiring oxygen for 
bactericidal effect seems to suggest the involvement of reactive oxygen species. 
However, oxygen-dependent transport of the peptide across the outer membrane cannot 
be completely ruled out. Using luminol and terephthalate has not been successful at 
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detecting the ROS formation. Therefore, more experimental data are required to resolve 
the issue. For example, ROS sensitive fluorescent dye, DCFDA (2',7'-dichlorofluorescin 
diacetate) could be used for better ROS detection. 
 
 Figure 7.1 Bactericidal activities of the peptides in aerobic versus anaerobic 
conditions. 
A. baumannii strain #1791 was treated with 50 or 200 µg/mL P307 or P307SQ-8C for 2 h at 
37°C in 50 mM Tris-HCl (pH 7.5 or 8.8) under aerobic or anaerobic conditions. Serial 
dilutions were plated for cfu counting. The error bars show standard deviation and the 
black horizontal lines mark the limit of detection. 
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7.1.2 ATCC 17978 caused clearings on agar overlay containing DH5α 
 The surrounding area of A. baumannii strain ATCC 17978 colony was clear on an 
agar overlay of E. coli strain DH5α (Figure 7.2). The clearing could be induced by 
ATCC 17978 killing DH5α and the potential killing agents are phages, Type VI secretion 
system and phage lysins. 
 Although most phages are strain specific, there also exist polyvalent phages that 
infect more than one genus (85). The possibility was examined by plaque forming assay. 
The prophages from ATCC 17978 were induced with mitomycin C and concentrated with 
PEG-8000. The phage preparation was spotted on an agar overlay of DH5α, but no 
plaque was observed. Most likely, phages were not involved in the killing. 
 A. baumannii has been shown to use type VI secretion system (T6SS) for bacterial 
competition (86). This possibility has not been thoroughly examined but ATCC 17978 
indeed possessed T6SS in its genome and deleting the essential components could reveal 
whether T6SS is used for DH5α killing. 
 Last, but not least, phage lysins of Gram-negative bacteria have been shown to 
perform non-phage related functions. For example, in Salmonella phage lysins are 
retained from past infections and become orphan phage enzymes as indicated by the 
difference in DNA composition in the up and downstream of the gene (87). They are 
utilized by the bacterium for infection (88), toxin secretion (89) and virulence (87). Such 
uses of phage lysins by A. baumannii have not been reported before. However, A. 
baumannii strains are usually poly-lysogenic and some of the prophages are no longer 
intact. According to PHAge Search Tool (PHAST) analysis (90), ATCC 17978 possessed 
three prophages, two of which are intact and the third questionable. To investigate 
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whether the lysins are used to kill DH5α, we are investigating the RNA expression level 
of the three lysins in ATCC 17978. 
 
 Figure 7.2 Clearing zone around A. baumannii ATCC 17978 colony on E. coli 




 PlyF309 (GenBank Accession Number KJ740397.1) is the second most active 
among the 21 distinct lysins isolated from a genomic library of prophages inside 13 A. 
baumannii strains (47). According to a National Center for Biotechnology Information 
Basic Local Alignment Search Tool (BLAST) search, it is composed of an N-terminal 
catalytic domain (glycosyl hydrolase family 108) and a C-terminal cell-wall binding 
domain (peptidoglycan binding 3) (Figure 7.1). The molecular weight of PlyF309 is ~21 
kDa and the isoelectric point is 8.40. The lysin was purified and its in vitro bactericidal 
activities were analyzed. 
 
 Figure 7.3 Domain organization of PlyF309. 
7.2.2 MATERIALS AND METHODS 
7.2.2.1 Expression and purification 
 Overnight culture of E. coli DH5α with the pBAD24-PlyF309 construct was 
diluted 1:100 in LB containing 100 µg/ml ampicillin and was incubated at 37°C, with 
shaking at 200 rpm, until reaching an optical density at 600 nm (OD600) of 0.5. The 
expression of PlyF309 was induced by the addition of 0.2% arabinose, and expression 
continued overnight at 30°C. The cells were collected, resuspending in 50 mM sodium 
phosphate (pH 6.8), and homogenized using an Emulsiflex-C5 homogenizer (Avestin). 
The cellular debris was removed by centrifugation (16,000 × g for 45 min at 4°C) 
followed by sterile filtration (0.22 µm) to generate a crude lysate. The crude lysate of 
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PlyF309 in 50 mM sodium phosphate (pH 6.8) was applied to a HiTrap SP FF column 
(GE Healthcare Life Sciences, Uppsala, Sweden) using the Äkta fast protein liquid 
chromatography (FPLC) system (GE Healthcare Life Sciences), and fractions were eluted 
with a linear gradient of 2 M NaCl. Peaks of interest were pooled and BCA assay was 
used to determine the concentration. 
7.2.2.2 In vitro bactericidal assays 
 PlyF309 was biochemically characterized to understand the effects on its in vitro 
bactericidal activity by pH, monovalent cation Na+, divalent cations (Ca2+ and Mg2+), 
chelating agent EDTA and growth phases (log and stationary). For these assays, A. 
baumannii strain #1791 was washed and re-suspended in respective buffer at OD595~1.0 
(>108 cfu/mL) and 250 µg/mL of PlyF309 was used. The strain specificity of PlyF309 
was investigated with 15 A. baumannii strains #1775-1777 and #1788-#1799 using 250 
µg/mL PlyF309, 250 µM EDTA and 37.5 mM Tris buffer (pH 8.0). The experiments 
were conducted at least in duplicate. 
7.2.3 RESULTS 
7.2.3.1 In vitro characterization 
 PlyF309 was most active in high pH (8.0 and 8.8) and was not tolerant to 
monovalent or divalent cations. The higher the EDTA concentrations, the more active 
PlyF309. The stationary phase bacteria are the most sensitive among the growth phases 
and PlyF309 showed higher activities against strains #1775, #1776, #1777, #1788, #1790, 
#1791, #1795, #1798 and #1799 than the rest of the 6 strains (Table 7.1). 
  
 72 
Table 7.1 Summary of PlyF309 activities in different assay conditions 
Assay condition Percent killing 
Sodium acetate buffer (pH 5.2) 
Tris-HCl buffer (pH 6.07) 
Tris-HCl buffer (pH 6.8) 
Tris-HCl buffer (pH 8.0) 






75 mM NaCl 
150 mM NaCl 
0 
14.29 
5 mM CaCl2 
5 mM MgCl2 
0 
0 
0.1 mM EDTA 
0.25 mM EDTA 




Early log phase 2 h 
Log phase 4 h 
Late log phase 8 h 





































 The theoretical isoelectric points of PlyF309 catalytic and binding domains are 
5.01 and 9.56, respectively, which means that the catalytic domain is negatively charged 
and the binding domain is positively charged in the buffers tested. Better killing activities 
were achieved with high pH and high EDTA concentrations whereas the cations 
diminished the activities, indicating that the outer membrane barrier did impede PlyF309 
from getting access to the peptidoglycan. It is also intriguing that PlyF309 showed 
growth phase and strain preferences. PlyF309 was also much less active than PlyF307. 
However, these results are likely due to the use of higher number of bacteria (108 vs 106 
cfu/mL used for PlyF307 assays) while the concentration of the PlyF309 was only 2.5 
times higher (250 µg/mL vs 100 µg/mL used for PlyF307 assays). 
7.2.5 ACKNOWLEDGMENTS 





1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. 
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob 
Agents Chemother 51:3471–3484. 
2. Potron A, Poirel L, Nordmann P. 2015. Emerging broad-spectrum resistance in 
Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and 
epidemiology. Int J Antimicrob Agents 45:568–585. 
3. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin Infect 
Dis 51:79–84. 
4. Dijkshoorn L, Nemec A. 2008. The Diversity of the genus Acinetobacter. In 
Gerischer, U (ed.), Acinetobacter Molecular Biology. Caister Academic Press. 
5. Doughari HJ, Ndakidemi PA, Human IS, Benade S. 2011. The ecology, biology 
and pathogenesis of Acinetobacter spp.: An overview. Microbes Environ 26:101–
112. 
6. Gonzalez-Villoria AM, Valverde-Garduno V. 2016. Antibiotic-resistant 
Acinetobacter baumannii increasing success remains a challenge as a nosocomial 
pathogen. Journal of Pathogens. 
7. Almasaudi SB. 2016. Acinetobacter spp. as nosocomial pathogens: Epidemiology 
and resistance features. Saudi Journal of Biological Sciences. 
8. European Centre for Disease Prevention and Control. 2016. Carbapenem-
resistant Acinetobacter baumannii in healthcare settings. In. Stockholm: ECDC. 
9. Stirland RM, Hillier VF, Steyger MG. 1969. Analysis of hospital bacteriological 
data. J clin Path suppl (Coll Path) 3:82–86. 
10. Morohoshi T, Saito T. 1977. β-lactamase and β-lactam antibiotics resistance in 
Acinetobacter anitratum (syn.: A. calcoaceticus). J Antibiot 30:969–973. 
11. Beck-Sagué CM, Jarvis WR, Brook JH, Culver DH, Potts A, Gay E, Shotts 
BW, Hill B, Anderson RL, Weinstein MP. 1990. Epidemic bacteremia due to 
Acinetobacter baumannii in five intensive care units. Am J Epidemiol 132:723–
733. 
12. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, 
Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An 
update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. 
13. World Health Organization WHO. 2017. Global priority list of antibiotic-
resistant bacteria to guide research, discovery, and development of new antibiotics. 
 75 
14. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: Emergence 
of a successful pathogen. Clin Microbiol Rev 21:538–582. 
15. Beggs CB, Kerr KG, Snelling AM. 2006. Acinetobacter spp. and the clinical 
environment. Indoor and Built Environ 15:19–24. 
16. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. 1998. Survival of 
Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic 
isolates. J Clin Microbiol 36:1938–1941. 
17. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: 
Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5:939–951. 
18. Centers for Disease Control and Prevention (CDC). 2013. Antibiotic resistance 
threats in the United States, 2013. 
19. Choi CH, Lee JS, Lee YC, Park TI, Lee JC. 2008. Acinetobacter baumannii 
invades epithelial cells and outer membrane protein A mediates interactions with 
epithelial cells. BMC Microbiol 8. 
20. Choi CH, Hyun SH, Lee JY, Lee JS, Lee YS, Kim SA, Chae JP, Yoo SM, Lee 
JC. 2008. Acinetobacter baumannii outer membrane protein A targets the nucleus 
and induces cytotoxicity. Cell Microbiol, 2nd ed. 10:309–319. 
21. Jin JS, Kwon S-O, Moon DC, Gurung M, Lee JH, Kim Il S, Lee JC. 2011. 
Acinetobacter baumannii secretes cytotoxic outer membrane protein A via outer 
membrane vesicles. PLoS ONE 6:e17027. 
22. Moon DC, Choi CH, Lee JH, Choi C-W, Kim H-Y, Park JS, Kim Il S, Lee JC. 
2012. Acinetobacter baumannii outer membrane protein A modulates the 
biogenesis of outer membrane vesicles. J Microbiol 50:155–160. 
23. Johnson TL, Waack U, Smith S, Mobley H, Sandkvist M. 2015. Acinetobacter 
baumannii is dependent on the type II secretion system and its substrate lipA for 
lipid utilization and in vivo fitness. J Bacteriol 198:711–719. 
24. Dorsey CW, Beglin MS, Actis LA. 2003. Detection and analysis of iron uptake 
components expressed by Acinetobacter baumannii clinical isolates. J Clin 
Microbiol 41:4188–4193. 
25. Lees Miller RG, Iwashkiw JA, Scott NE, Seper A, Vinogradov E, Schild S, 
Feldman MF. 2013. A common pathway for O‐linked protein‐glycosylation and 
synthesis of capsule in Acinetobacter baumannii. Mol Microbiol 89:816–830. 
26. Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox 
AD, St Michael F, Vinogradov EV, Campagnari AA. 2010. Identification and 
characterization of a glycosyltransferase involved in Acinetobacter baumannii 
lipopolysaccharide core biosynthesis. Infect Immun 78:2017–2023. 
 76 
27. Doi Y, Murray GL, Peleg AY. 2015. Acinetobacter baumannii: Evolution of 
antimicrobial resistance—Treatment options. Semin Respir Crit Care Med 36:85–
98. 
28. Ramirez MS, Don M, Merkier AK, Bistué AJS, Zorreguieta A, Centrón D, 
Tolmasky ME. 2010. Naturally competent Acinetobacter baumannii clinical 
isolate as a convenient model for genetic studies. J Clin Microbiol 48:1488–1490. 
29. Viehman JA, Nguyen MH, Doi Y. 2014. Treatment options for carbapenem-
resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 
74:1315–1333. 
30. Reardon S. 2014. Phage therapy gets revitalized. Nature. 
31. Sulakvelidze A, Alavidze Z, Morris JG. 2001. Bacteriophage therapy. 
Antimicrob Agents Chemother 45:649–659. 
32. Debarbieux L, Pirnay J-P, Verbeken G, De Vos D, Merabishvili M, Huys I, 
Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C. 2016. A 
bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett 
363:fnv225. 
33. Kingwell K. 2015. Bacteriophage therapies re-enter clinical trials. Nat Rev Drug 
Discov 14:515–516. 
34. Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M. 2016. 
Bacteriophage therapy: A regulatory perspective. J Antimicrob Chemother 
71:2071–2074. 
35. Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK. 2016. Genetically 
engineered phages: A review of advances over the last decade. Microbiol Mol Biol 
Rev 80:523–543. 
36. Fischetti VA, Nelson D, Schuch R. 2006. Reinventing phage therapy: Are the 
parts greater than the sum? Nat Biotechnol 24:1508–1511. 
37. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacteriophage 
lysin with broad lytic activity protects against mixed infection by Streptococcus 
pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents 
Chemother 57:2743–2750. 
38. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006. PlyC: A 
multimeric bacteriophage lysin. PNAS 103:10765–10770. 
39. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and 
kills Bacillus anthracis. Nature 418:884–889. 
40. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr Opin 
 77 
Microbiol 11:393–400. 
41. Lim J-A, Shin H, Kang D-H, Ryu S. 2012. Characterization of endolysin from a 
Salmonella Typhimurium-infecting bacteriophage SPN1S. Res Microbiol 
163:233–241. 
42. Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, 
Lavigne R. 2013. Characterization of five novel endolysins from Gram-negative 
infecting bacteriophages. Appl Microbiol Biotechnol 97:4369–4375. 
43. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, 
Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay J-P, Miller S, Volckaert 
G, Lavigne R. 2014. Engineered endolysin-based “Artilysins” to combat 
multidrug-resistant Gram-negative pathogens. mBio 5:e01379–14. 
44. Lukacik P, Barnard TJ, Buchanan SK. 2012. Using a bacteriocin structure to 
engineer a phage lysin that targets Yersinia pestis. Biochem Soc Trans 40:1503–
1506. 
45. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, 
Noinaj N, Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan 
SK. 2012. Structural engineering of a phage lysin that targets gram-negative 
pathogens. PNAS 109:9857–9862. 
46. Lai M-J, Lin N-T, Hu A, Soo P-C, Chen L-K, Chen L-H, Chang K-C. 2011. 
Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin 
(LysAB2) against both Gram-positive and Gram-negative bacteria. Appl Microbiol 
Biotechnol 90:529–539. 
47. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, 
Schuch R, Fischetti VA. 2015. Novel phage lysin capable of killing the 
multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse 
bacteremia model. Antimicrob Agents Chemother 59:1983–1991. 
48. Murphy KM. 2011. Janeway's Immunobiology, 8 ed. Garland Science. 
49. Dürr UHN, Sudheendra US, Ramamoorthy A. 2006. LL-37, the only human 
member of the cathelicidin family of antimicrobial peptides. Biochim Biophys 
Acta 1758:1408–1425. 
50. Fahrner RL, Dieckmann T, Harwig SSL, Lehrer RI, Eisenberg D, Feigon J. 
1996. Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide 
from porcine leukocytes. Chem Biol 3:543–550. 
51. Song C, Weichbrodt C, Salnikov ES, Dynowski M, Forsberg BO, Bechinger 
B, Steinem C, de Groot BL, Zachariae U, Zeth K. 2013. Crystal structure and 
functional mechanism of a human antimicrobial membrane channel. PNAS 
110:4586–4591. 
 78 
52. Chen H-L, Su P-Y, Chang Y-S, Wu S-Y, Liao Y-D, Yu H-M, Lauderdale T-L, 
Chang K, Shih C. 2013. Identification of a novel antimicrobial peptide from 
human hepatitis B virus core protein arginine-rich domain (ARD). PLoS Pathog 
9:e1003425. 
53. Li J, Koh J-J, Liu S, Lakshminarayanan R, Verma CS, Beuerman RW. 2017. 
Membrane active antimicrobial peptides: Translating mechanistic insights to 
design. Front Neurosci 11:73. 
54. Andersson DI, Hughes D, Kubicek-Sutherland JZ. 2016. Mechanisms and 
consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updat 
26:43–57. 
55. Yele AB, Thawal ND, Sahu PK, Chopade BA. 2012. Novel lytic bacteriophage 
AB7-IBB1 of Acinetobacter baumannii: Isolation, characterization and its effect 
on biofilm. Arch Virol 157:1441–1450. 
56. Popova AV, Zhilenkov EL, Myakinina VP, Krasilnikova VM, Volozhantsev 
NV. 2012. Isolation and characterization of wide host range lytic bacteriophage 
AP22 infecting Acinetobacter baumannii. FEMS Microbiol Lett 332:40–46. 
57. Jin J, Li Z-J, Wang S-W, Wang S-M, Huang D-H, Li Y-H, Ma Y-Y, Wang J, 
Liu F, Chen X-D, Li G-X, Wang X-T, Wang Z-Q, Zhao G-Q. 2012. Isolation 
and characterization of ZZ1, a novel lytic phage that infects Acinetobacter 
baumannii clinical isolates. BMC Microbiol 12:156. 
58. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC 
Bioinformatics 2008 9:1 9:40. 
59. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: A unified platform for 
automated protein structure and function prediction. Nat Protoc 5:725–738. 
60. Roy A, Yang J, Zhang Y. 2012. COFACTOR: An accurate comparative 
algorithm for structure-based protein function annotation. Nucleic Acids Res 
40:W471–W477. 
61. Mól AR, Fontes W, Castro MS. 2016. NetWheels: A web application to create 
high quality peptide helical wheel and net projections. 
62. Gerstmans H, Rodríguez-Rubio L, Lavigne R, Briers Y. 2016. From endolysins 
to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. 
Biochem Soc Trans 44:123–128. 
63. Wellings DA, Atherton E. 1997. [4] Standard Fmoc protocols. Methods Enzymol 
289:44–67. 
64. Knorr R, Trzeciak A, Bannwarth W, Gillessen D. 1989. New coupling reagents 
in peptide chemistry. Tetrahedron Lett 30:1927–1930. 
 79 
65. CLSI. 2012. M07-A9: Methods for dilution antimicrobial susceptibility tests for 
bacteria that grow aerobically; approved standard—ninth edition. Clinical and 
Laboratory Standards Institute, Wayne, PA. 
66. Djurkovic S, Loeffler JM, Fischetti VA. 2005. Synergistic killing of 
Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and 
penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob 
Agents Chemother 49:1225–1228. 
67. Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial 
peptide buforin II: Buforin II kills microorganisms by penetrating the cell 
membrane and inhibiting cellular functions. Biochem Biophys Res Commun 
244:253–257. 
68. Saugar JM, Alarcón T, López-Hernández S, López-Brea M, Andreu D, Rivas 
L. 2002. Activities of polymyxin B and cecropin A-,melittin peptide CA(1-8)M(1-
18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents 
Chemother 46:875–878. 
69. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti 
VA. 2011. A novel chimeric lysin shows superiority to mupirocin for skin 
decolonization of methicillin-resistant and -sensitive Staphylococcus aureus 
strains. Antimicrob Agents Chemother 55:738–744. 
70. J Boohaker R, W Lee M, Vishnubhotla P, L M Perez J, R Khaled A. 2012. 
The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 
19:3794–3804. 
71. Mares J, Kumaran S, Gobbo M, Zerbe O. 2009. Interactions of 
lipopolysaccharide and polymyxin studied by NMR spectroscopy. J Biol Chem 
284:11498–11506. 
72. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility 
breakpoints. Clin Microbiol Rev 20:391–408. 
73. Rodríguez Baño J, Marti S, Soto S, Fernández Cuenca F, Cisneros JM, 
Pachón J, Pascual A, Martínez Martínez L, McQueary C, Actis LA, Vila J. 
2008. Biofilm formation in Acinetobacter baumannii: Associated features and 
clinical implications. Clin Microbiol Infect 14:276–278. 
74. Irvin RT, MacAlister TJ, Costerton JW. 1981. 
Tris(hydroxymethyl)aminomethane buffer modification of Escherichia coli outer 
membrane permeability. J Bacteriol 145:1397–1403. 
75. Clifton LA, Skoda MWA, Le Brun AP, Ciesielski F, Kuzmenko I, Holt SA, 
Lakey JH. 2015. Effect of divalent cation removal on the structure of Gram-
negative bacterial outer membrane models. Langmuir 31:404–412. 
 80 
76. Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. 2009. Mechanisms of drug 
combinations: Interaction and network perspectives. Nat Rev Drug Discov 8:111–
128. 
77. Wen F, Rubin-Pitel SB. 2009. Engineering of therapeutic proteins, pp. 153–176. 
In Park, SJ, Cochran, JR (eds.), Protein engineering and design. CRC Press. 
78. Lam SJ, O'Brien-Simpson NM, Pantarat N, Sulistio A, Wong EHH, Chen Y-
Y, Lenzo JC, Holden JA, Blencowe A, Reynolds EC, Qiao GG. 2016. 
Combating multidrug-resistant Gram-negative bacteria with structurally 
nanoengineered antimicrobial peptide polymers. Nat Microbiol 1:16162. 
79. Roca I, Espinal P, Vila-Farrés X, Vila J. 2012. The Acinetobacter baumannii 
oxymoron: Commensal hospital dweller turned pan-drug-resistant menace. Front 
Microbio 3:148. 
80. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A 
common mechanism of cellular death induced by bactericidal antibiotics. Cell 
130:797–810. 
81. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. 2012. 
Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a 
hydroxyl radical death pathway. Antimicrob Agents Chemother 56:5642–5649. 
82. Dwyer DJ, Camacho DM, Kohanski MA, Callura JM, Collins JJ. 2012. 
Antibiotic-induced bacterial cell death exhibits physiological and biochemical 
hallmarks of apoptosis. Mol Cell 46:561–572. 
83. Liu Y, Imlay JA. 2013. Cell death from antibiotics without the involvement of 
reactive oxygen species. Science 339:1210–1213. 
84. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by 
bactericidal antibiotics does not depend on reactive oxygen species. Science 
339:1213–1216. 
85. Souza KA, Ginoza HS, Haight RD. 1972. Isolation of a polyvalent bacteriophage 
for Escherichia coli, Klebsiella pneumoniae, and Aerobacter aerogenes. J Virol 
9:851–856. 
86. Carruthers MD, Nicholson PA, Tracy EN, Munson RS Jr. 2013. Acinetobacter 
baumannii utilizes a type VI secretion system for bacterial competition. PLoS 
ONE 8:e59388. 
87. Michalska K, Brown RN, Li H, Jedrzejczak R, Niemann GS, Heffron F, Cort 
JR, Adkins JN, Babnigg G, Joachimiak A. 2013. New sub-family of lysozyme-
like proteins shows no catalytic activity: Crystallographic and biochemical study 
of STM3605 protein from Salmonella Typhimurium. J Struct Funct Genomics 
14:1–10. 
 81 
88. Alam MM, Tsai LL, Rollins SM, Sheikh A, Khanam F, Bufano MK, Yu Y, 
Wu-Freeman Y, Kalsy A, Sultana T, Sayeed MA, Jahan N, LaRocque RC, 
Harris JB, Leung DT, Brooks WA, Calderwood SB, Charles RC, Qadri F, 
Ryan ET. 2013. Identification of in vivo-induced bacterial proteins during human 
infection with Salmonella enterica serotype Paratyphi A. Clin Vaccine Immunol 
20:712–719. 
89. Hodak H, Galán JE. 2013. A Salmonella Typhi homologue of bacteriophage 
muramidases controls typhoid toxin secretion. EMBO Rep 14:95–102. 
90. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: A Fast 
Phage Search Tool. Nucleic Acids Res 39:W347–W352. 
	  
